Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

New EACS 2025 data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

The "miracle tool" HIV medicine lenacapavir will be sold in South Africa from as early as March or April 2026 according to ...

Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...

The US Department of State has announced a life-saving development to bring US-based Gilead Sciences’ breakthrough drug ...

This tiny nation was winning in its fight against HIV. Then Trump cut foreign aid - With the single stroke of Trump’s pen, ...

A new study led by researchers at the George Washington University and published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, finds that nearly half of ...

The first symptoms of HIV are often similar to the flu, including fever, fatigue, and body aches. However, some people don't ...

For the 2.3 million residents of Lesotho, the announcement of massive cuts to the U.S. aid that sustained much of the small ...